Product Description
BR55, an ultrasound contrast agent functionalized with a heterodimer peptide targeting the vascular endothelial growth factor receptor 2 (VEGFR2), was evaluated in vitro and in vivo, demonstrating its potential for specific tumor detection.
Mechanisms of Action: Imaging Agent, VEGFR2
Novel Mechanism: Yes
Modality: Diagnostic Agent
Route of Administration: Injection
FDA Designation: Fast Track - Crohn Disease *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Bracco Imaging
Company Location: Europe
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 2
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Breast Diseases|Inflammatory Breast Cancer|Ovarian Cancer|Ovarian Diseases|Thyroid Cancer
Phase 1: Pulmonary Fibrosis
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
CTR20221230 |
CTR20221230 | P1 |
Completed |
Pulmonary Fibrosis |
2024-05-24 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
CTR20220634 |
CTR20220634 | P2 |
Completed |
Ovarian Cancer|Ovarian Diseases|Thyroid Cancer|Breast Diseases|Inflammatory Breast Cancer |
2024-01-21 |
2025-04-29 |